Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minoru Kato

Showing results (61-70 of 173) with videos related to

Pageof 18
Sort By:
Journal of Clinical Medicine|November 21, 2018
Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane ChemotherapyYasuomi Shimizu, Satoshi Tamada, Minoru Kato, et al.
Hinyokika Kiyo. Acta Urologica Japonica|May 25, 2022
[A Case of Metastatic Urothelial Carcinoma with Pseudoprogression of Liver Metastasis during the Treatment with Pembrolizumab]Hiroo Masuda, Minoru Kato, Hiroki Yoshiuchi, et al.
Experimental and Therapeutic Medicine|December 14, 2018
Steroid sulfatase promotes invasion through epithelial-mesenchymal transition and predicts the progression of bladder cancerYasuomi Shimizu, Satoshi Tamada, Minoru Kato, et al.
Immunotherapy|July 15, 2026
Clinical impact of opioid use in patients with urothelial carcinoma treated with pembrolizumab: a single center retrospective studyYusuke Ishigami, Masaya Takahashi, Hitomi Nakatsukasa, et al.
Urologic Oncology|December 2, 2021
A retrospective study on optimal number of cycles of the first-line platinum-based chemotherapy for metastatic urothelial carcinomaShoma Yamamoto, Minoru Kato, Yuji Takeyama, et al.
Basic and Clinical Andrology|July 21, 2018
A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancerJumpei Asakawa, Taro Iguchi, Satoshi Tamada, et al.
Prostate International|June 21, 2018
Kamikihito improves cancer-related fatigue by restoring balance between the sympathetic and parasympathetic nervous systemsSatoshi Tamada, Kyoko Ebisu, Sayaka Yasuda, et al.
Medicina (Kaunas, Lithuania)|March 28, 2024
Comparison of Oncological Outcomes between Transperitoneal and Retroperitoneal Approaches in Laparoscopic Nephroureterectomies for Upper Tract Urothelial CarcinomaTaiyo Otoshi, Takeshi Yamasaki, Taisuke Matsue, et al.
International Journal of Clinical Oncology|November 15, 2025
Prognostic impact and site-specific efficacy of systemic therapies in locally advanced or metastatic urothelial carcinoma: in an era of expanding therapeutic optionsShoma Yamamoto, Minoru Kato, Taisuke Matsue, et al.
Toxicology and Applied Pharmacology|September 4, 2013
Diphenylarsinic acid, a chemical warfare-related neurotoxicant, promotes liver carcinogenesis via activation of aryl hydrocarbon receptor signaling and consequent induction of oxidative DNA damage in ratsMin Wei, Takanori Yamada, Shotaro Yamano, et al.
Pageof 18

Showing results (61-70 of 173) with videos related to

Sort By:
Pageof 18
Journal of Clinical Medicine|November 21, 2018
Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane ChemotherapyYasuomi Shimizu, Satoshi Tamada, Minoru Kato, et al.
Hinyokika Kiyo. Acta Urologica Japonica|May 25, 2022
[A Case of Metastatic Urothelial Carcinoma with Pseudoprogression of Liver Metastasis during the Treatment with Pembrolizumab]Hiroo Masuda, Minoru Kato, Hiroki Yoshiuchi, et al.
Experimental and Therapeutic Medicine|December 14, 2018
Steroid sulfatase promotes invasion through epithelial-mesenchymal transition and predicts the progression of bladder cancerYasuomi Shimizu, Satoshi Tamada, Minoru Kato, et al.
Immunotherapy|July 15, 2026
Clinical impact of opioid use in patients with urothelial carcinoma treated with pembrolizumab: a single center retrospective studyYusuke Ishigami, Masaya Takahashi, Hitomi Nakatsukasa, et al.
Urologic Oncology|December 2, 2021
A retrospective study on optimal number of cycles of the first-line platinum-based chemotherapy for metastatic urothelial carcinomaShoma Yamamoto, Minoru Kato, Yuji Takeyama, et al.
Basic and Clinical Andrology|July 21, 2018
A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancerJumpei Asakawa, Taro Iguchi, Satoshi Tamada, et al.
Prostate International|June 21, 2018
Kamikihito improves cancer-related fatigue by restoring balance between the sympathetic and parasympathetic nervous systemsSatoshi Tamada, Kyoko Ebisu, Sayaka Yasuda, et al.
Medicina (Kaunas, Lithuania)|March 28, 2024
Comparison of Oncological Outcomes between Transperitoneal and Retroperitoneal Approaches in Laparoscopic Nephroureterectomies for Upper Tract Urothelial CarcinomaTaiyo Otoshi, Takeshi Yamasaki, Taisuke Matsue, et al.
International Journal of Clinical Oncology|November 15, 2025
Prognostic impact and site-specific efficacy of systemic therapies in locally advanced or metastatic urothelial carcinoma: in an era of expanding therapeutic optionsShoma Yamamoto, Minoru Kato, Taisuke Matsue, et al.
Toxicology and Applied Pharmacology|September 4, 2013
Diphenylarsinic acid, a chemical warfare-related neurotoxicant, promotes liver carcinogenesis via activation of aryl hydrocarbon receptor signaling and consequent induction of oxidative DNA damage in ratsMin Wei, Takanori Yamada, Shotaro Yamano, et al.
Pageof 18